Phase 1 Study of 14C-BMS-986504 MRTX1719 to Understand Drug Processing in Adults With Advanced Solid Tumors Having MTAP Gene Deletion

What this Trial Is About

Researchers are evaluating the mass balance, metabolism, elimination, and drug levels of 14C-BMS-986504 MRTX1719 in adults with advanced solid tumors that have a specific genetic deletion called homozygous methylthioadenosine phosphorylase MTAP deletion. This Phase 1 study focuses on understanding how this drug behaves in the body of participants whose cancers have this genetic feature and who have limited treatment options. The study has two parts In Part A, participants receive a single oral dose of radiolabeled 14C-BMS-986504 to track the drugs movement and breakdown in the body. In Part B, participants receive non-radiolabeled BMS-986504 starting from the first day of the cycle until criteria for stopping treatment are met. This approach helps researchers observe drug levels and effects over time. Participants will undergo various assessments including blood and urine tests up to two weeks after dosing to measure drug concentration, elimination, and distribution. Researchers will also monitor safety by tracking adverse events and laboratory abnormalities for up to two years. The study aims to gather detailed pharmacokinetic data and observe any side effects during and after treatment.

A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion